Reduce liver cancer return after surgery using anti–TIM-3
Part of Cancer, Digestive system clinical trials.
This trial studies whether blocking TIM-3 (an immune “brake”) can help stop hepatocellular carcinoma (liver cancer) from coming back after a curative surgery. It may help by improving your immune system’s ability to find and control remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) confirmed by pathology (tissue biopsy/removal).
- Your cancer is early stage (CNLC stage Ia or Ib) and you’re having a radical (curative) resection.
- After surgery, at least one higher-risk feature applies (for example tumor 5+ cm, microvascular invasion, multiple tumors, or high AFP).
- You must be in good general health for treatment (ECOG 0–1) and have acceptable liver function (Child-Pugh A or B).
- You must meet blood test minimums (white blood cells, lymphocytes, and platelets) and kidney/liver enzyme limits.
- You can’t have certain recent treatments or immune-suppressing medicines before enrollment, and you must avoid other cancer trials right before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests whether giving chemotherapy, immunotherapy, and targeted drugs before surgery helps prevent liver cancer from coming back in patients with high-risk tumors. You would receive treatment to shrink the tumor before your scheduled surgery.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial tests a combination of treatments for liver cancer that can be surgically removed. It adds immunotherapy drugs (Iparomlimab and Tuvonralimab, together called QL1706) and targeted therapy (Lenvatinib) to a procedure called TACE (chemoembolization) to see if this approach shrinks the tumor and lowers the chance of recurrence after surgery.
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.